BiographyDr. Goff is a Member of the Faculty and Vice Chair for Research in the Department of Psychiatry at New York University Langone Medical Center (NYULMC). He is also Director of the Nathan S. Kline Institute for Psychiatric Research. Prior to coming to NYULMC, Dr. Goff was the Director of the Schizophrenia Clinical and Research Program at the Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School. An international expert in translational neuroscience research in schizophrenia, Dr. Goff is also an award-winning clinical expert and teacher. He has received the Stanley Dean Award for Research in Schizophrenia, the Wayne Fenton Award for Exceptional Clinical Care and the American Psychiatric Association Award for Mentorship in Biological Psychiatry.
Dr. Goff’s research is directed towards identifying biological mechanisms that contribute to the onset of schizophrenia and that shape the clinical course. Results from this work are leading to novel, individualized interventions for prevention and to promote recovery. His research team includes experts in brain imaging, genetics, pharmacology, cognitive behavioral therapy and cognitive remediation. Along with Dr. Michelle Izmirly, he is establishing a specialized outpatient clinic at Bellevue Hospital for individuals with early psychosis to study new approaches for improving long-term outcomes.
Pfizer, Cephalon, and Janssen
Pfizer, Cephalon, Janssen, Xenoport, Dainippon Sumitomo, Solvay/Wyeth, Bristol-Meyer Squibb, Versumed, Letters and Science, SG Cowen, Vista Research, Organon, Proteus, Genactics, Forest, Xytis, MedReviews LLC, and Vanda Pharmaceuticals
Last Updated: 7/27/2010